GlassScriptPhysician profile
Indrani Sen Hightower
NPI 1952410458
$18,702.50
in general payments reported to CMS, 2019-2025
82 companies · $191 in 2025
The $191 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,806 · 2020: $2,358 · 2021: $3,335 · 2022: $3,067 · 2023: $3,058 · 2024: $3,887 · 2025: $191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,022 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,021.84 |
| Education | $115.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $3,040.18 | 2019-2025 | Mavenclad |
| Celgene Corporation | $1,451.64 | 2021-2024 | Zeposia |
| Abbvie INC. | $1,187.07 | 2021-2024 | Ubrelvy, Botox, Qulipta |
| Biogen, INC. | $1,126.89 | 2019-2024 | Vumerity, Tysabri, Plegridy |
| Novartis Pharmaceuticals Corporation | $970.37 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $905.94 | 2020-2024 | Zeposia |
| Ucb, INC. | $880.35 | 2019-2024 | Zilbrysq, Briviact |
| Pfizer INC. | $543.85 | 2019-2024 | |
| Avanir Pharmaceuticals, INC. | $391.79 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $379.55 | 2019-2024 | Ultomiris |
| Jazz Pharmaceuticals INC. | $375.38 | 2019-2024 | Xywav, Epidiolex |
| Acadia Pharmaceuticals INC | $326.20 | 2019-2024 | Nuplazid |
| Ani Pharmaceuticals, INC. | $306.29 | 2022-2025 | Purified Cortrophin Gel |
| Biohaven Pharmaceutical Holding Company LTD. | $302.32 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $293.80 | 2019-2024 | Austedo Xr |
Show all 82 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Indrani Sen Hightower listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.